Market Structure
European MedTech companies frequently approach Switzerland the way they'd approach France, Germany, or Spain: as a single national market with a single regulatory and purchasing path. That assumption doesn't hold — and understanding why is the first real step in planning market entry here.
There is no national purchasing body
Switzerland is a confederation of 26 cantons, each with meaningful autonomy over healthcare policy within the framework of the federal health insurance law (KVG in German, LAMal in French). Each canton maintains its own hospital list — the "Spitalliste" — which determines which hospitals are authorized to provide which services under mandatory health insurance. There is no federal agency that centrally purchases medical equipment or supplies on behalf of Swiss hospitals.
Purchasing happens at the hospital or group level
In practice, procurement decisions for MedTech products are made by individual hospitals or hospital groups — public, private, or university-affiliated — each with its own purchasing committee, budget cycle, and clinical evaluation process. Large cantons like Zürich or Vaud have multiple hospital groups operating independently of one another. This means a successful sale to one hospital group tells you relatively little about your prospects with the next one, even within the same canton.
Regulatory approval is separate from commercial access
Swissmedic, Switzerland's medical device regulator, governs market authorization. Getting Swissmedic approval is a necessary step, but it is entirely separate from winning individual hospital procurement decisions. Since the EU-Switzerland mutual recognition agreement for medical devices lapsed in 2021, non-Swiss manufacturers must also appoint a Swiss Authorized Representative (CH-REP) to place a device on the market here — a regulatory step distinct from, and required in addition to, having a CE mark. Regulatory clearance opens the door; it doesn't get you through it.
What this means for market entry
- A national marketing campaign will underperform a targeted, canton-by-canton approach.
- Early traction in one canton or hospital group is a signal, not proof of broader market fit.
- Understanding which cantons and hospital groups are realistic near-term targets for your specific product category is foundational work — not a detail to sort out later.
This structural reality is exactly why Alpine's engagements start with Market Validation: mapping where your product category has genuine traction before any commercial outreach begins.